Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri

A technology based on sulfanyl and indole, applied in the field of norepinephrine reuptake inhibitors, can solve problems such as impossible progress

Inactive Publication Date: 2007-01-17
H LUNDBECK AS
View PDF13 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No real progress in pharmacotherapy of depression and anxiety is possible without addressing these issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
  • 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
  • 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0694] Another aspect of the present invention relates to the following processes for the preparation of the compounds of the present invention.

[0695] The preparation method of the compound of the present invention

[0696] The preparation of the compound of the present invention is as follows:

[0697] Method 1 (for compounds of formula IA), alkylation of amines of formula III with alkylated derivatives of formula II:

[0698]

[0699] where R 1 -R 13 As defined herein, L is a leaving group such as, for example, halogen, mesylate or tosylate;

[0700] The compound of formula IA is thus isolated as a free base or a salt thereof such as a pharmaceutically acceptable acid addition salt.

[0701] Method 2 (for compounds of formula IA), reduction of amide derivatives of formula IV below,

[0702]

[0703] where R 1 -R 13 as defined herein;

[0704] The compound of formula IA is thus isolated as a free base or a salt thereof such as a pharmaceutically acceptable ac...

Embodiment 12

[0765] Example 12-(1H-indol-3-ylsulfanyl)-N,N-dimethylbenzamide

[0766] N,N,N',N'-tetramethyl-2,2'-dithiobenzamide (Elworthy, Todd R.; Ford, Anthony P.D.W.; Bantle, Gary W. ; Morgans, David J.; Ozer, Rachel S.; et al. J.Med.Chem.40, 1997, 2674-2687) (12.80 g, 35.5 mmol) dissolved in 1,2-dichloroethane (200 mL), Sulfonyl chloride (2.9 mL, 4.84 g, 35.9 mmol) was added carefully under argon with stirring, the reaction mixture was stirred at room temperature for 15 min, and the resulting solution was added slowly (dropwise) under argon over ice Cooled (0° C.) solution of indole (8.4 g, 71.7 mmol) in anhydrous DMF (180 mL). The mixture was stirred at 0 °C under Ar for 2.5 h, then water (180 mL) and saturated NaHCO were added 3 The aqueous solution (150 mL) was quenched, and to the resulting emulsion was added ethyl acetate (250 mL). The organic phases were combined and washed with brine (100 mL). The aqueous phase was further extracted with ethyl acetate (2×100 mL), the combin...

Embodiment 2

[0791] 2-(1H-Indol-3-ylsulfanyl)-N-methylbenzamide

[0792] Carbonyldiimidazole (11 mmol) was added to 2-(1H-indol-3-ylsulfanyl)benzoic acid (Hamel, P.; Girard, M.; Tsou, N.N.; J. Heterocycl. Chem. 36, 1999 , 643-652) (10 mmol) in anhydrous THF (200 mL) and refluxed under argon for 60 minutes, methylamine (1M in THF; 40 mL) was slowly added to the reaction mixture, The mixture was stirred at room temperature for 16 hours, the mixture was evaporated in vacuo and the product was purified by column chromatography on silica gel using ethyl acetate as eluent.

[0793] The following compounds were prepared in a similar manner:

[0794] 2-(5-Fluoro-1H-indol-3-ylsulfanyl)-N-methylbenzamide

[0795] 2-(6-Fluoro-1H-indol-3-ylsulfanyl)-N-methylbenzamide

[0796] 2-(2-Methyl-1H-indol-3-ylsulfanyl)-N-methylbenzamide

[0797] 2-(4-Methyl-1H-indol-3-ylsulfanyl)-N-methylbenzamide

[0798] 2-(4-Chloro-1H-indol-3-ylsulfanyl)-N-methylbenzamide

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to aniline derivatives of the general formula I and their use as serotonin reuptake inhibitors and preferably also norepinephrine reuptake inhibitors in the treatment of depression, anxiety, affective disorders, pain disorders, attention deficit hyperactivity disorder (ADHD) and stress urinary incontinence.

Description

technical field [0001] The present invention relates to compounds as serotonin reuptake inhibitors, and preferably also as norepinephrine reuptake inhibitors, and to the medical use of said compounds, e.g. in the treatment of depression and anxiety, affective disorders, pain disorders (pain Disorder), attention deficit hyperactivity disorder (attention deficit hyperactivity disorder, ADHD) and stress urinary incontinence (stress urinary incontinence). Background technique [0002] Most antidepressants in use today can be divided into three categories: [0003] 1) Monoamine oxidase inhibitors (MAOIs), [0004] 2) biogenic amine neurotransmitter [serotonin (5-HT), norepinephrine (NE), and dopamine (DA)] transporter reuptake blockers, and [0005] 3) Modulators, especially blockers of one or more 5-HT and / or NE receptors. [0006] Because depression is associated with a relative deficiency of biogenic amines, the use of 5-HT and / or NE receptor blockers (ie, antagonists of 5-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D209/30C07D401/12A61K31/404A61P29/00C07D403/06C07D413/06
CPCC07D401/12C07D209/30C07D403/06C07D413/06A61P13/00A61P25/00A61P25/24A61P29/00A61K31/403A61K31/404
Inventor J·克勒K·朱尔J·塞伯格M·B·诺尔加德
Owner H LUNDBECK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com